New compound counters F508del mutation, boosts Trikafta’s effects
Scientists have synthesized a new compound that can boost the activity of the CFTR protein carrying the most common mutation that causes cystic fibrosis (CF). In cell models, the compound was able to further increase the activity of approved CFTR modulators. The compound’s development was described in the…